Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Predicted to enable microtubule binding activity. Predicted to be involved in several processes, including axonal transport; positive regulation of insulin secretion involved in cellular response to glucose stimulus; and regulation of synaptic activity. Predicted to act upstream of or within regulation of insulin secretion involved in cellular response to glucose stimulus. Predicted to be located in several cellular components, including dense body; microtubule; and vesicle. Predicted to be active in cytoplasmic microtubule. Is expressed in alimentary system; central nervous system; dorsal root ganglion; eye; and nasal cavity. Orthologous to human SYBU (syntabulin). [provided by Alliance of Genome Resources, Feb 2025]